Accessibility Menu
Sernova Biotherapeutics logo

Sernova Biotherapeutics(OTC) SEOVF

Market Cap$31.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-64%
5 Year-92%
1 Year-41%
1 Month-4%
$0.07
-15.92%
-0.01Today
Sernova Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.082026-08-14
Sernova Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.91%USD 0.082026-08-07
1 month-4.36%USD 0.092026-07-15
3 month-30.05%USD 0.122026-05-15
Year to date-12.73%USD 0.092025-12-31
1 year-41.21%USD 0.142025-08-14
3 year-86.75%USD 0.622023-08-15
5 year-92.18%USD 1.052021-08-13
Since inception-64.45%USD 0.232012-04-25

Sernova Biotherapeutics Financials at a Glance

Market Cap

$31.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$11.84M

EPS (TTM)

-$0.03

P/E Ratio

-3.23

Dividend

$0.00

Beta (Volatility)

0.42 (Low)

Price

$0.07

Volume

158,412

Open

$0.08

Previous Close

$0.07

Daily Range

$0.07 - $0.08

52-Week Range

$0.07 - $0.15

Estimated Earnings Date

Sep 10, 2026

SEOVF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sernova Biotherapeutics

Sernova Corp. is a Canadian biotechnology company focused on advanced regenerative medicine therapeutics. Established in 1998 and headquartered in London, the firm is dedicated to developing innovative treatments, particularly through its proprietary "Cell Pouch" system.

Products and Services
  • Cell Pouch system for therapeutic cell implantation
  • Immune-protected therapeutic cells in collaboration with AgeX Therapeutics
  • Research partnerships to enhance cell therapy platforms
Growth Outlook
  • Continued clinical development of the Cell Pouch system
  • Strategic collaborations to enhance product offerings
  • Focus on chronic conditions like diabetes and hemophilia
Financial Highlights
  • Recent quarterly net income of -$3.23 million
  • Trailing twelve months (TTM) revenue of $0
  • Cash and cash equivalents of $1.05 million as of April 2026
Sernova Corp. operates in a promising sector with a focus on innovative medical solutions. The Cell Pouch system aims to address chronic conditions, which presents significant market potential. Despite recent financial challenges, including a net loss in the latest quarter, the company maintains a solid cash position to support ongoing research and development efforts. Collaborations with established firms and research institutions further enhance its growth prospects, positioning Sernova as a noteworthy player in the biotechnology industry.
AI Generated • Aug 9, 2026

Industry

Biotechnology

Sector

Health Care

Employees

8

CEO

Jonathan M. N. Rigby, MBA

Website

www.sernova.com

Headquarters

Mississauga, ON L5A 4H2, CA

SEOVF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

55.85%

Return on Capital

N/A

Return on Assets

-771.32%

Earnings Yield

-30.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$31.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

377.64M

Volume

158.41K

Avg. Volume

33.01K

Financials (TTM)

Gross Profit

-CA$204.64K

Operating Income

-CA$10.28M

EBITDA

-CA$10.04M

Operating Cash Flow

-CA$5.50M

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$5.50M

Cash & ST Invst.

CA$1.05M

Total Debt

CA$2.45M

Sernova Biotherapeutics Performance Analysis

Sernova Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-10-31CAD 0N/A
20232023-10-31CAD 0N/A
20242024-10-31CAD 0N/A
20252025-10-31CAD 0N/A
Sernova Biotherapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-31N/A
Q42025-10-31N/A
Q12026-01-31N/A
Q22026-04-30N/A
Sernova Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-10-31CAD -0.07208.0%
20232023-10-31CAD -0.1037.5%
20242024-10-31CAD -0.08-19.2%
20252025-10-31CAD -0.03-55.6%
Sernova Biotherapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-07-31-24.0%
Q42025-10-3146.8%
Q12026-01-31-6.1%
Q22026-04-30-31.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$4.43K

+87.2%

Gross Margin

0.00%

N/A

Market Cap

$31.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.89M

N/A

Employees

8

N/A

Net Income

-CA$3.23M

+14.6%

EBITDA

-CA$2.29M

+33.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$1.05M

-47.3%

Total Debt

CA$2.45M

-48.2%

Accounts Receivable

CA$116.80K

-73.0%

Inventory

CA$0.00

N/A

Long Term Debt

CA$229.16K

-81.2%

Short Term Debt

CA$2.22M

-36.9%

Return on Assets

-7.71%

N/A

Return on Invested Capital

1.09%

N/A

Free Cash Flow

-CA$2.21M

+42.5%

Operating Cash Flow

-CA$2.21M

+42.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MMIRFMedMira Inc.
$0.04+0.00%
DTCFFDefence Therapeutics Inc.
$0.34+2.08%
MDDVFMedical Developments International Limited
$0.33+0.00%
PVCTProvectus Biopharmaceuticals, Inc.
$0.06+3.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About SEOVF

What is the current price of Sernova Biotherapeutics?

Sernova Biotherapeutics is trading at $0.07 per share.

What is the 52-week range for Sernova Biotherapeutics?

Over the past 52 weeks, Sernova Biotherapeutics has traded between $0.07 and $0.15.

How much debt does Sernova Biotherapeutics have?

As of the most recent reporting period, Sernova Biotherapeutics reported total debt of CA$1.80M.

How much cash does Sernova Biotherapeutics have on hand?

Sernova Biotherapeutics reported CA$773.75K in cash and cash equivalents in its most recent financial results.

What is Sernova Biotherapeutics’s dividend yield?

Sernova Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services